id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-260034-a1y0enrg	Karsulovic, Claudio	mTORC inhibitor Sirolimus deprograms monocytes in “cytokine storm” in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome	2020-07-13		.txt	text/plain	930	61	44	title: mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosislike syndrome Human M1 monocytes in vitro were able to express higher levels of IL-6 and IL-1β after LPS stimulation (8) (Fig. 1) . When monocytes are treated in vitro with sirolimus, and mTORC blocker, they are unable to express M1 proteins even in presence of LPS. With this data and previous reports of its use in influenza pneumonia (13) , it seems reasonable to think that the SARS-CoV2 induced sHLH-Like syndrome could be successfully slowed or terminated by sirolimus, due to its action blocking the migration of monocytes to lung tissue. We propose at least compassionate use of sirolimus in SARS-CoV2 patients who are classified as high risk of ominous progression or are currently using tocilizumab, corticosteroids and/or J o u r n a l P r e -p r o o f protease inhibitors and Hscore shows high probability of sHLH.	./cache/cord-260034-a1y0enrg.txt	./txt/cord-260034-a1y0enrg.txt